Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 06:58:34 28/06/2024 BST			5-day change	1st Jan Change
0.28 ^AUD	-12.50%		-24.32%	-68.89%

05-23	Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials	MT
04-15	Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	MT

Zelda Therapeutics Ltd Announces Address Change of Registered Office

January 10, 2017 at 09:26 pm

Zelda Therapeutics Ltd. advised that, effective immediately, the company's address details will change to: Registered Office, Level 6, 105 St Georges Terrace, PERTH WA 6000, postal address: PO Box 5457, PERTH WA 6831.

Latest news about Zelira Therapeutics Limited

Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials	05-23	MT
Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	04-15	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	01-08	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	11-15
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Zelira Therapeutics Limited Announces Board Changes	31/05/23	CI
Transcript : Zelira Therapeutics Limited - Special Call	31/05/23
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	22/05/23	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	21/05/23	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	15/03/23	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	13/03/23	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Transcript : Zelira Therapeutics Limited - Special Call	22/02/23
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	20/02/23	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	15/02/23	MT
Zelira Therapeutics Secures R&D Tax Rebate	30/01/23	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	21/11/22	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	16/11/22
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets	20/09/22	CI
Zelira Therapeutics Enrolls Two-Thirds of Patients for Diabetic Nerve Pain Medication	15/09/22	MT
Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial	14/09/22	CI
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22	CI
Zelira Therapeutics Limited Auditor Raises 'Going Concern' Doubt	30/08/22	CI
Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany	21/07/22	CI

Chart Zelira Therapeutics Limited

Duration

Period

More charts

Company Profile

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZELIRA THERAPEUTICS LIMITED	-68.89%	2.12M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs